Lutonix™
Going the Distance
Treat long femoropopliteal lesions with the longest length DCB* The Lutonix™ 018 DCB may be used for lesions up to 300 mm in
length, which can help to reduce cost and increase procedural
.
018 DCB
Lutonix™ 018 DCB
In.Pact™ DCB
Only DCB available up to 300 mm Limited up to 250 mm
Stellarex™ DCB
Limited up to 200 mm
Ranger™ DCB Not drawn to scale
Limited up to 200 mm
* As of May 2021 on the U.S. market The Lutonix™
popliteal arteries with reference vessel diameter of 4-7 mm, and (ii) after pre-dilatation, for treatment of stenotic lesions of dysfunctional native arteriovenous dialysis fistulae that are 4 mm to 7 mm in diameter and up to 80 mm in length. Warning: A signal for increased risk of late mortality has been identified following the use of paclitaxel-coated balloons and paclitaxel-eluting stents for femoropopliteal arterial disease beginning approximately 2-3 years post-treatment compared with the use of non-drug coated devices. Physicians should discuss this late mortality signal and the benefits and risks of available treatment options with their patients.
018 Drug Coated Balloon PTA catheter is indicated for percutaneous transluminal angioplasty after appropriate vessel preparation, of de novo, restenotic, or in-stent restenotic lesions up to 300 mm in length in native superficial femoral or
Lutonix are trademarks of Becton, Dickinson and Company or an affiliate. All other trademarks are the properties of their respective owners. Illustrations by Mike Austin. © 2021 BD. All Rights Reserved. Bard Peripheral Vascular, Inc. |
www.bardpv.com | 1 800 321 4254 | 1625 W. 3rd Street Tempe, AZ 85281 BD-21403v1
Please consult product labels and instructions for use for indications, contraindications, hazards, warnings and precautions.
BD, the BD Logo, and
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40
